This work was first aimed to assess the role of PU.1 in regulating the expression of miR‐29b in non‐APL cells, in order to identify agonists that, through upmodulation of this transcription factor, could be beneficial in DNA hypomethylation‐based therapies. This evidence concerns the gene SPI1 and acute promyelocytic leukemia.